In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Guidance programme 1 selected

Guidance programme

Area of interest

Showing 211 to 220 of 301

TitleTypeExpected publication date
Polihexanide 0.8 mg/ml eye drops for treating acanthamoeba keratitis in people 12 years and over [ID6497]Technology appraisal guidance
Povorcitinib for treating moderate to severe active hidradenitis suppurativa after a TNF-alpha inhibitor [ID6569]Technology appraisal guidance
Ravulizumab for preventing kidney events in people with chronic kidney disease at high risk after a cardiopulmonary bypass [ID6632]Technology appraisal guidanceTBC
Rebisufligene etisparvovec for treating mucopolysaccharidosis type IIIA [ID6540]Technology appraisal guidanceTBC
Regorafenib for treating advanced gastrointestinal stromal tumours [ID1056]Technology appraisal guidance
Remibrutinib for treating chronic spontaneous urticaria inadequately controlled by H1-antihistamines [ID6356]Technology appraisal guidance
Renal cell carcinoma Pathways Pilot [ID6186]Technology appraisal guidanceTBC
Repotrectinib for treating NTRK fusion-positive advanced solid tumours in people 12 years and over [TSID12147]Technology appraisal guidanceTBC
Resmetirom for treating non-alcoholic steatohepatitis and liver fibrosis [ID6529]Technology appraisal guidance
Resminostat for maintenance treatment of advanced mycosis fungoides or Sezary syndrome [ID6478]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All